Daniel J. George, MD, on RCC: Study Results on Adjuvant Treatment

2018 Genitourinary Cancers Symposium
Tweet this page

Daniel J. George, MD, of Duke University Medical Center, discusses phase III findings on adjuvant sunitinib in patients with high-risk renal cell carcinoma, in an exploratory pharmacogenomic analysis (Abstract 576).

Advertisement

Advertisement



Advertisement